Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases.
- Author:
Hyeki CHO
1
;
Yuri CHO
;
Eun Ju CHO
;
Jeong Hoon LEE
;
Su Jong YU
;
Kook Hwan OH
;
Kyoungbun LEE
;
Syifa MUSTIKA
;
Jung Hwan YOON
;
Yoon Jun KIM
Author Information
- Publication Type:Case Reports
- Keywords: Tenofovir; Acute Kidney Injury; Drug-Related Side Effects and Adverse Reactions; Chronic Hepatitis B; Kidney Tubules
- MeSH: Acute Kidney Injury/etiology; Aged; Antiviral Agents/adverse effects/therapeutic use; Creatinine/blood; Glomerular Filtration Rate; Hepatitis B, Chronic/*drug therapy; Humans; Kidney Tubules/pathology; Male; Microscopy, Electron; Middle Aged; Necrosis; Risk Factors; Tenofovir/adverse effects/*therapeutic use
- From:Clinical and Molecular Hepatology 2016;22(2):286-291
- CountryRepublic of Korea
- Language:English
- Abstract: Tenofovir disoproxil fumarate (TDF) is effective against chronic hepatitis B (CHB) infection and its use is increasing rapidly worldwide. However, it has been established that TDF is associated with renal toxicity in human immunodeficiency virus-infected patients, while severe or symptomatic TDF-associated nephrotoxicity has rarely been reported in patients with CHB. Here we present two patients with TDF-associated nephrotoxicity who were being treated for CHB infection. The first patient was found to have clinical manifestations of proximal renal tubular dysfunction and histopathologic evidence of acute tubular necrosis at 5 months after starting TDF treatment. The second patient developed acute kidney injury at 17 days after commencing TDF, and he was found to have membranoproliferative glomerulonephritis with acute tubular injury. The renal function improved in both patients after discontinuing TDF. We discuss the risk factors for TDF-associated renal toxicity and present recommendations for monitoring renal function during TDF therapy.
